Advertisement

Topics

Chemotherapy Induced Neutropenia CIN Market Insights, Epidemiology and Market Forecast2023 [Report Updated: 01032017] Prices from USD $4950

02:00 EDT 31 Jul 2017 | BioPortfolio Reports

DelveInsight's Chemotherapy Induced Neutropenia CIN Market Insights, Epidemiology
and Market Forecast2023 Report provides an overview of the disease and global market
trends of the Chemotherapy Induced Neutropenia for the seven major markets i.e., United
States, Europe France, Germany, Italy, Spain, UK and Japan, as well as rest of Europe RoE
and rest of the world RoW. The Report covers the therapeutics market revenue, treatment
practice and Chemotherapy Induced Neutropenia CIN forecasted market share from 2017 to
2023 segmented by seven major markets. In addition, the report provides the historical and
forecasted of incident cases at risk of Chemotherapy Induced Neutropenia CIN in 10 cancer
indications till 2023.
The report covers the number of patients for 10 cancer indications i.e., Breast Cancer,
Leukemia, Prostate Cancer, Lung Cancer, Cervical Cancer, Pancreatic Cancer, Colorectal Cancer,
Ovarian Cancer, Hodgkin's disease and NonHodgkin Lymphoma, who are at risk of developing
CIN as an adverse event of the chemotherapies of respective cancers.
Neupogen Filgrastim, developed and marketed by Amgen is the first GCSF approved for
chemotherapyinduced neutropenia CIN in 1991. Its PEGylated formulation, Neulasta was
later approved in 2002. Filgrastim i.e., Neupogen and PEGylated filgrastim Neulasta contribute
to majority of the market size, of CIN. However, New Chemical Entities are expected to launch
in the near future. According to DelveInsight, the worldwide CIN market is estimated to
increase at a CAGR of 3.37% for the forecast period i.e., 20132023.
The report is built using data and information sourced from proprietary databases, primary and
secondary research and inhouse Forecast model analysis by Publisher team of industry experts.Chemotherapy Induced Neutropenia Market 7MM
Chemotherapy Induced Neutropenia Market forecasting
Chemotherapy Induced Neutropenia Sales forecasting
Chemotherapy Induced Neutropenia Market segments
Chemotherapy Induced Neutropenia Epidemiology
Chemotherapy Induced Neutropenia Pipeline products and technologies
Chemotherapy Induced Neutropenia Competitive landscape
Chemotherapy Induced Neutropenia SWOT analysis
Chemotherapy Induced Neutropenia Market Driver's and barriers
Chemotherapy Induced Neutropenia Key Companies and Funding

Original Article: Chemotherapy Induced Neutropenia CIN Market Insights, Epidemiology and Market Forecast2023 [Report Updated: 01032017] Prices from USD $4950

NEXT ARTICLE

More From BioPortfolio on "Chemotherapy Induced Neutropenia CIN Market Insights, Epidemiology and Market Forecast2023 [Report Updated: 01032017] Prices from USD $4950"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...